Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis.
Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC.
Kosmidis ML, et al. Among authors: dalakas mc.
Neurol Neuroimmunol Neuroinflamm. 2019 Jun 10;6(4):e581. doi: 10.1212/NXI.0000000000000581. eCollection 2019 Jul.
Neurol Neuroimmunol Neuroinflamm. 2019.
PMID: 31355317
Free PMC article.
In patients 2 and 4, in whom 3-year longitudinal data were available, no effect on disease progression was noted. CONCLUSIONS: In this long-term, open-label study, canakinumab showed small, but not clinically appreciable, stabilizing benefits in 2 of 5 patients with sIBM o …
In patients 2 and 4, in whom 3-year longitudinal data were available, no effect on disease progression was noted. CONCLUSIONS: In this long- …